Identification/NN
of/IN
New/NN
Potential/JJ
APE1/NN
Inhibitors/NNS
by/IN
Pharmacophore/NN
Modeling/JJ
and/CC
Molecular/JJ
Docking/JJ
./.
====================
Apurinic/apyrimidinic/JJ
endonuclease/NN
1/CD
(/(
APE1/NN
)/)
is/VBZ
an/DT
enzyme/NN
responsible/JJ
for/IN
the/DT
initial/JJ
step/NN
in/IN
the/DT
base/NN
excision/NN
repair/NN
pathway/NN
and/CC
is/VBZ
known/VBN
to/TO
be/VB
a/DT
potential/JJ
drug/NN
target/NN
for/IN
treating/VBG
cancers/NNS
,/,
because/IN
its/PRP$
expression/NN
is/VBZ
associated/VBN
with/IN
resistance/NN
to/TO
DNA-damaging/JJ
anticancer/JJ
agents/NNS
./.
====================
Although/IN
several/JJ
inhibitors/NNS
already/RB
have/VBP
been/VBN
identified/VBN
,/,
the/DT
identification/NN
of/IN
novel/JJ
kinds/NNS
of/IN
potential/JJ
inhibitors/NNS
of/IN
APE1/NN
could/MD
provide/VB
a/DT
seed/JJ
for/IN
the/DT
development/NN
of/IN
improved/JJ
anticancer/JJ
drugs/NNS
./.
====================
For/IN
this/DT
purpose/NN
,/,
we/PRP
first/RB
classified/VBN
known/VBN
inhibitors/NNS
of/IN
APE1/NN
./.
====================
According/VBG
to/TO
the/DT
classification/NN
,/,
we/PRP
constructed/VBD
two/CD
distinct/JJ
pharmacophore/NN
models/NNS
./.
====================
We/PRP
screened/VBD
more/RBR
than/IN
3/CD
million/NN
lead-like/JJ
compounds/NNS
using/VBG
the/DT
pharmacophores/NNS
./.
====================
Hits/NNS
that/DT
fulfilled/JJ
the/DT
features/NNS
of/IN
the/DT
pharmacophore/NN
models/NNS
were/VBD
identified/VBN
./.
====================
In/IN
addition/NN
to/TO
the/DT
pharmacophore/NN
screen/NN
,/,
we/PRP
carried/VBD
out/RP
molecular/JJ
docking/NN
to/TO
prioritize/VB
hits/VBZ
./.
====================
Based/VBN
on/IN
these/DT
processes/NNS
,/,
we/PRP
ultimately/RB
identified/VBD
1,338/CD
potential/JJ
inhibitors/NNS
of/IN
APE1/NN
with/IN
predicted/VBN
binding/NN
affinities/NNS
to/TO
the/DT
enzyme/NN
./.
====================
DNA/NN
damage/NN
occurs/VBZ
naturally/RB
and/CC
due/JJ
to/TO
the/DT
environment/NN
,/,
altering/VBG
the/DT
cell/NN
’/NN
s/NNS
abilities/NNS
that/DT
are/VBP
encoded/VBN
by/IN
the/DT
DNA/NN
,/,
and/CC
may/MD
lead/VB
to/TO
diseases/NNS
,/,
like/IN
cancer/NN
./.
====================
Cells/NNS
respond/VBP
to/TO
DNA/NN
damage/NN
by/IN
DNA/NN
repair/NN
and/CC
cellular/JJ
apoptosis/NN
[/(
1/CD
,/,
2/CD
]/)
./.
====================
Apurinic/apyrimidinic/JJ
endonuclease/NN
(/(
APE/NN
)/)
is/VBZ
an/DT
enzyme/NN
that/DT
identifies/VBZ
damaged/VBN
apurinic/apyrimidinic/JJ
sites/NNS
in/IN
DNA/NN
,/,
cuts/NNS
the/DT
phosphodiester/NN
bond/NN
in/IN
the/DT
backbone/NN
of/IN
the/DT
sites/NNS
,/,
and/CC
has/VBZ
critical/JJ
roles/NNS
in/IN
the/DT
base/NN
excision/NN
pathway/NN
[/(
3/CD
]/)
./.
====================
APE1/NN
has/VBZ
recently/RB
been/VBN
noted/VBN
as/IN
a/DT
potential/JJ
drug/NN
target/NN
for/IN
treating/VBG
cancer/NN
,/,
in/IN
that/DT
overexpression/NN
of/IN
the/DT
enzyme/NN
has/VBZ
been/VBN
observed/VBN
and/CC
shown/VBN
to/TO
be/VB
associated/VBN
with/IN
a/DT
poor/JJ
response/NN
to/TO
cancer/NN
treatment/NN
,/,
such/JJ
as/IN
radiation/NN
and/CC
anticancer/JJ
drugs/NNS
,/,
and/CC
a/DT
lower/JJR
overall/JJ
survival/NN
rate/NN
[/(
4–7/CD
]/)
./.
====================
Antineoplastic/JJ
agents/NNS
that/WDT
are/VBP
to/TO
treat/VB
cancers/NNS
are/VBP
known/VBN
to/TO
induce/VB
the/DT
expression/NN
of/IN
APE1/NN
,/,
increasing/VBG
the/DT
resistance/NN
of/IN
tumor/NN
cells/NNS
to/TO
drug/NN
treatment/NN
./.
====================
Thus/RB
,/,
compounds/NNS
that/WDT
inhibit/VBP
the/DT
activity/NN
of/IN
APE1/NN
could/MD
be/VB
potential/JJ
anticancer/JJ
drugs/NNS
with/IN
DNA-damaging/JJ
antineoplastic/JJ
agents/NNS
used/VBN
in/IN
the/DT
clinic/NN
[/(
8/CD
]/)
./.
====================
For/IN
this/DT
reason/NN
,/,
there/EX
have/VBP
been/VBN
several/JJ
attempts/NNS
to/TO
develop/VB
compounds/NNS
targeting/VBG
APE1/NN
./.
====================
Currently/RB
,/,
although/IN
there/EX
is/VBZ
no/DT
approved/JJ
drug/NN
yet/RB
,/,
three/CD
candidates—7-nitroindole-2-carboxylic/JJ
acid/NN
(/(
also/RB
known/VBN
as/IN
CRT0044876/NN
)/)
[/(
9/CD
,/,
10/CD
]/)
,/,
lucanthone/NN
(/(
also/RB
known/VBN
as/IN
Miracil/NN
D/NN
)/)
[/(
9/CD
]/)
,/,
and/CC
methoxyamine/JJ
(/(
trademark/VBP
TRC102/NN
)/)
—are/RB
known/VBN
to/TO
inhibit/VB
APE1/NN
activity/NN
and/CC
are/VBP
under/IN
examination/NN
in/IN
clinical/JJ
trials/NNS
./.
====================
Lucanthone/NN
and/CC
CRT0044876/NN
have/VBP
rings/NNS
similar/JJ
to/TO
the/DT
deoxyribose/NN
sugar/VBP
ring/NN
without/IN
a/DT
base/NN
and/CC
many/JJ
hydrogen/NN
bond/NN
acceptors/NNS
that/DT
can/MD
interact/VB
with/IN
hydrogen/NN
bond/NN
donors/NNS
in/IN
the/DT
active/JJ
site/NN
of/IN
APE1/NN
./.
====================
These/DT
properties/NNS
lead/VBP
APE1/NN
to/TO
stick/VB
in/IN
the/DT
site/NN
and/CC
prevent/VBP
it/PRP
from/IN
repairing/VBG
DNA/NN
damage/NN
[/(
11/CD
]/)
./.
====================
Methoxyamine/NN
is/VBZ
known/VBN
to/TO
attack/VB
the/DT
open-ring/JJ
form/VBP
of/IN
AP/NN
sites/NNS
to/TO
form/VB
an/DT
oxime/NN
linkage/NN
./.
====================
In/IN
other/JJ
words/NNS
,/,
methoxyamine/NN
blocks/VBZ
APE1/NN
from/IN
accessing/VBG
the/DT
lesion/NN
site/NN
rather/RB
than/IN
targeting/VBG
the/DT
enzyme/NN
directly/RB
./.
====================
This/DT
may/MD
lead/VB
to/TO
nonspecific/JJ
off-target/NN
effects/NNS
[/(
12/CD
,/,
13/CD
]/)
./.
====================
Although/IN
several/JJ
inhibitors/NNS
of/IN
APE1/NN
have/VBP
been/VBN
discovered/VBN
,/,
most/JJS
potent/JJ
compounds/NNS
have/VBP
weaknesses/NNS
[/(
14/CD
]/)
./.
====================
Thus/RB
,/,
it/PRP
is/VBZ
necessary/JJ
to/TO
find/VB
novel/JJ
kinds/NNS
of/IN
potential/JJ
inhibitors/NNS
targeting/VBG
APE1/NN
./.
====================
Here/RB
,/,
we/PRP
present/VBP
out/IN
work/NN
,/,
in/IN
which/WDT
we/PRP
applied/VBD
pharmacophore/NN
modeling/VBG
and/CC
virtual/JJ
screening/NN
./.
====================
The/DT
overall/JJ
procedures/NNS
we/PRP
carried/VBD
out/RP
are/VBP
illustrated/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
We/PRP
constructed/VBD
pharmacophore/NN
models/NNS
by/IN
capturing/VBG
the/DT
common/JJ
features/NNS
of/IN
known/VBN
inhibitors/NNS
of/IN
APE1/NN
./.
====================
The/DT
modes/NNS
were/VBD
used/VBN
to/TO
screen/VB
a/DT
vast/JJ
number/NN
of/IN
lead-like/JJ
compounds/NNS
,/,
and/CC
molecular/JJ
docking/NN
was/VBD
used/VBN
to/TO
prioritize/VB
the/DT
hits/NNS
of/IN
the/DT
screen/NN
./.
====================
Selection/NN
of/IN
ligands/NNS
for/IN
pharmacophore/NN
modeling/VBG
====================
From/IN
the/DT
ChEMBL/NN
[/(
15/CD
]/)
database/NN
,/,
we/PRP
retrieved/VBD
52/CD
compounds/NNS
known/VBN
to/TO
be/VB
targets/NNS
of/IN
APE1/NN
and/CC
51/CD
compounds/NNS
with/IN
an/DT
IC50/NN
of/IN
less/RBR
than/IN
10/CD
μM/NN
./.
====================
By/IN
eliminating/VBG
redundancy/NN
,/,
the/DT
number/NN
of/IN
compounds/NNS
was/VBD
reduced/VBN
into/IN
83/CD
./.
====================
The/DT
list/NN
did/VBD
not/RB
contain/VB
methoxyamine/NN
;/:
so/RB
,/,
methoxyamine/NN
was/VBD
also/RB
added/VBN
to/TO
the/DT
list/NN
./.
====================
We/PRP
clustered/VBD
these/DT
84/CD
compounds/NNS
by/IN
Tanimoto/NN
distance/NN
,/,
based/VBN
on/IN
the/DT
PubChem/JJ
fingerprint/NN
[/(
16/CD
]/)
,/,
and/CC
finally/RB
categorized/VBD
them/PRP
into/IN
two/CD
groups/NNS
by/IN
excluding/VBG
two/CD
outliers/NNS
(/(
CHEMBL1213633/NN
and/CC
CHEMBL313493/NN
)/)
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
A/DT
total/JJ
of/IN
49/CD
molecules/NNS
in/IN
group/NN
1/CD
(/(
Fig/NN
./.
====================
3/CD
)/)
and/CC
33/CD
molecules/NNS
in/IN
group/NN
2/CD
(/(
Fig/NN
./.
====================
4/CD
)/)
were/VBD
used/VBN
to/TO
generate/VB
pharmacophore/NN
models/NNS
1/CD
and/CC
2/CD
,/,
respectively/RB
./.
====================
Generation/NN
of/IN
pharmacophore/NN
model/NN
====================
Ligandscout/RB
tools/NNS
4.1/CD
[/(
17/CD
]/)
was/VBD
used/VBN
to/TO
generate/VB
the/DT
ligand-based/JJ
pharmacophore/NN
models/NNS
./.
====================
Ligandscout/RB
is/VBZ
known/VBN
to/TO
be/VB
able/JJ
to/TO
increase/VB
the/DT
selectivity/NN
of/IN
a/DT
pharmacophore/NN
model/NN
with/IN
the/DT
excluded/VBN
volume/NN
feature/NN
./.
====================
To/TO
generate/VB
more/RBR
flexible/JJ
pharmacophore/NN
,/,
the/DT
threshold/NN
of/IN
the/DT
portion/NN
of/IN
partially/RB
matching/VBG
features/NNS
was/VBD
set/NN
to/TO
20/CD
%/NN
./.
====================
Pharmacophore/NN
screen/NN
====================
For/IN
the/DT
initial/JJ
set/NN
of/IN
the/DT
pharmacophore/NN
screen/NN
,/,
we/PRP
selected/VBD
a/DT
lead-like/JJ
subset/NN
[/(
18/CD
]/)
,/,
defined/VBN
by/IN
the/DT
ZINC/NN
database/NN
(/(
ZINC/NN
is/VBZ
not/RB
commercial/JJ
)/)
[/(
19/CD
]/)
./.
====================
Similar/JJ
to/TO
druglikeness/VB
[/(
20/CD
]/)
,/,
like/IN
Lipinski/NNP
’/CD
s/NNS
rule/NN
of/IN
5/CD
[/(
21/CD
]/)
,/,
lead-like/IN
compounds/NNS
are/VBP
defined/VBN
as/IN
being/VBG
large/JJ
enough/IN
to/TO
be/VB
validated/VBN
in/IN
experiments/NNS
but/CC
are/VBP
smaller/JJR
than/IN
most/JJS
drugs/NNS
,/,
optimized/VBN
too/RB
specifically/RB
,/,
and/CC
more/RBR
soluble/JJ
than/IN
their/PRP$
drug-like/JJ
compounds/NNS
./.
====================
ZINC/NN
provides/VBZ
a/DT
lead-like/JJ
subset/NN
fulfilling/VBG
leadlikeness/RBR
as/IN
follows/VBZ
:/:
(/(
1/CD
)/)
molecular/JJ
weight/NN
between/IN
250/CD
and/CC
350/CD
Da/NN
,/,
(/(
2/CD
)/)
partition/NN
coefficient/JJ
log/NN
p/NN
≤/CD
3.5/CD
,/,
and/CC
(/(
3/CD
)/)
no/DT
more/RBR
than/IN
seven/CD
rotatable/JJ
bonds/NNS
./.
====================
The/DT
structures/NNS
of/IN
lead-like/JJ
compounds/NNS
in/IN
medium/NN
pH/NN
were/VBD
downloaded/VBN
and/CC
converted/VBD
into/IN
a/DT
database/NN
for/IN
screening/NN
by/IN
idbgen/NN
,/,
a/DT
component/NN
of/IN
Ligandscout/JJ
./.
====================
We/PRP
carried/VBD
out/RP
pharmacophore/NN
screens/NNS
using/VBG
iscreen/VBN
in/IN
Ligandscout/JJ
for/IN
models/NNS
1/CD
and/CC
2/CD
independently/RB
./.
====================
Pharmacophore/RB
fit/NN
scores/VBZ
were/VBD
also/RB
calculated/VBN
by/IN
LigandScout/JJ
based/VBN
on/IN
the/DT
number/NN
of/IN
matching/VBG
pharmacophore/NN
features/NNS
and/CC
the/DT
root-mean-square/JJ
deviation/NN
of/IN
the/DT
pharmacophore/NN
alignment/NN
./.
====================
Molecule/NN
docking/NN
simulation/NN
====================
To/TO
prioritize/VB
the/DT
hits/NNS
of/IN
the/DT
pharmacophore/NN
screen/NN
,/,
we/PRP
docked/VBD
the/DT
hits/NNS
against/IN
previously/RB
determined/VBN
structures/NNS
of/IN
APE1/NN
[/(
22/CD
]/)
(/(
PDB/NN
ID/NN
:/:
1DEW/CD
)/)
using/VBG
AutoDock/NN
Vina/NN
[/(
23/CD
]/)
./.
====================
A/DT
binding/NN
site/NN
of/IN
APE1/NN
was/VBD
assigned/VBN
using/VBG
the/DT
fpocket/NN
algorithm/NN
[/(
24/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
84/CD
compounds/NNS
from/IN
the/DT
ChEMBL/NN
database/NN
were/VBD
first/JJ
collected/JJ
to/TO
generate/VB
a/DT
pharmacophore/NN
,/,
but/CC
their/PRP$
structures/NNS
and/CC
properties/NNS
were/VBD
too/RB
heterogeneous/JJ
to/TO
get/VB
common/JJ
features/NNS
./.
====================
Thus/RB
,/,
we/PRP
carried/VBD
out/RP
clustering/NN
and/CC
categorized/VBD
the/DT
compounds/NNS
into/IN
two/CD
groups/NNS
(/(
Figs/NNS
./.
====================
2–4/CD
)/)
./.
====================
For/IN
each/DT
group/NN
of/IN
compounds/NNS
,/,
we/PRP
generated/VBD
the/DT
corresponding/JJ
pharmacophore/NN
model/NN
./.
====================
Pharmacophore/NN
model/NN
1/CD
was/VBD
generated/VBN
by/IN
49/CD
compounds/NNS
from/IN
group/NN
1/CD
./.
====================
The/DT
model/NN
was/VBD
composed/VBN
of/IN
four/CD
features/NNS
(/(
one/CD
hydrophobic/JJ
centroid/NN
,/,
one/CD
aromatic/JJ
ring/NN
,/,
two/CD
hydrogen/NN
acceptors/NNS
)/)
and/CC
three/CD
exclusion/NN
volume/NN
spaces/VBZ
(/(
Fig/NN
./.
====================
5A/CD
)/)
./.
====================
Model/NN
2/CD
was/VBD
generated/VBN
by/IN
33/CD
compounds/NNS
from/IN
group/NN
2/CD
./.
====================
The/DT
model/NN
was/VBD
composed/VBN
of/IN
four/CD
features/NNS
(/(
one/CD
negative/JJ
ionizable/JJ
and/CC
three/CD
hydrogen/NN
bond/NN
acceptors/NNS
)/)
and/CC
12/CD
exclusion/NN
volume/NN
spaces/VBZ
(/(
Fig/NN
./.
====================
5B/NN
)/)
./.
====================
For/IN
3,563,829/CD
lead-like/JJ
compounds/NNS
retrieved/VBD
from/IN
the/DT
ZINC/NN
database/NN
,/,
we/PRP
performed/VBD
a/DT
pharmacophore/NN
screen/NN
based/VBN
on/IN
pharmacophore/NN
models/NNS
1/CD
and/CC
2/CD
independently/RB
./.
====================
Among/IN
multiple/JJ
subsets/NNS
provided/VBD
by/IN
ZINC/NN
,/,
we/PRP
chose/VBP
the/DT
lead-like/JJ
subset/NN
,/,
not/RB
the/DT
drug-like/JJ
set/NN
,/,
because/IN
we/PRP
aimed/VBD
to/TO
provide/VB
a/DT
list/NN
of/IN
potential/JJ
hits/VBZ
that/DT
could/MD
be/VB
optimized/VBN
further/RBR
by/IN
other/JJ
groups/NNS
,/,
as/IN
well/RB
as/IN
our/PRP$
group/NN
./.
====================
As/IN
a/DT
result/NN
,/,
400,153/CD
and/CC
290,742/CD
hits/VBZ
fulfilled/JJ
the/DT
features/NNS
of/IN
models/NNS
1/CD
and/CC
2/CD
,/,
respectively/RB
./.
====================
The/DT
intersection/NN
of/IN
the/DT
two/CD
lists/NNS
of/IN
hits/NNS
,/,
which/WDT
fulfilled/VBD
all/DT
features/NNS
of/IN
both/DT
models/NNS
,/,
consisted/VBD
of/IN
38,087/CD
compounds/NNS
./.
====================
To/TO
remove/VB
structurally/RB
similar/JJ
compounds/NNS
,/,
we/PRP
clustered/VBD
the/DT
38,087/CD
hits/VBZ
by/IN
hierarchical/JJ
clustering/NN
,/,
based/VBN
on/IN
the/DT
Tanimoto/NN
distance/NN
in/IN
PubChem/JJ
Fingerprint/JJ
./.
====================
According/VBG
to/TO
the/DT
result/NN
of/IN
the/DT
clustering/NN
,/,
we/PRP
ruled/VBD
out/RP
redundant/JJ
compounds/NNS
that/WDT
had/VBD
similar/JJ
compounds/NNS
(/(
Tanimoto/NN
coefficient/JJ
>/JJR
0.8/CD
)/)
./.
====================
Thus/RB
,/,
1,338/NN
hits/VBZ
eventually/RB
remained/VBD
as/IN
potential/JJ
inhibitors/NNS
of/IN
APE1/NN
./.
====================
We/PRP
carried/VBD
out/RP
molecular/JJ
docking/NN
of/IN
the/DT
hits/NNS
against/IN
APE1/NN
to/TO
prioritize/VB
the/DT
hits/NNS
using/VBG
AutoDock/NN
Vina/NN
./.
====================
Fig/NN
./.
====================
6/CD
depicts/VBZ
the/DT
distribution/NN
of/IN
the/DT
predicted/VBN
binding/NN
energies/VBZ
of/IN
the/DT
hits/NNS
of/IN
the/DT
pharmacophore/NN
screen/NN
by/IN
docking/VBG
./.
====================
After/IN
molecular/JJ
docking/NN
,/,
we/PRP
did/VBD
not/RB
filter/RBR
out/IN
compounds/NNS
based/VBN
on/IN
a/DT
particular/JJ
threshold/NN
of/IN
the/DT
predicted/VBN
value/NN
of/IN
the/DT
binding/NN
affinity/NN
but/CC
instead/RB
provide/VBP
the/DT
top/NN
10/CD
hits/VBZ
in/IN
Fig/NN
./.
====================
7/CD
,/,
their/PRP$
predicted/VBN
binding/NN
poses/VBZ
in/IN
Supplementary/JJ
Fig/NN
./.
====================
1/CD
,/,
and/CC
all/DT
of/IN
the/DT
hits/NNS
in/IN
Supplementary/JJ
Table/JJ
1/CD
./.
====================
This/DT
is/VBZ
because/IN
although/IN
Shityakov/NN
and/CC
Förster/NN
[/(
25/CD
]/)
reported/VBD
that/IN
a/DT
compound/NN
having/VBG
a/DT
binding/VBG
affinity/NN
predicted/VBN
by/IN
AutoDock/NN
Vina/NN
of/IN
lower/JJR
than/IN
−6/CD
kcal/mol/NN
could/MD
be/VB
considered/VBN
an/DT
active/JJ
hit/RB
,/,
the/DT
values/NNS
are/VBP
only/RB
predictive/JJ
and/CC
rely/RB
on/IN
a/DT
somewhat/RB
empirical/JJ
energy/NN
function/NN
./.
====================
In/IN
other/JJ
words/NNS
,/,
predicted/VBN
binding/NN
affinities/NNS
should/MD
be/VB
used/VBN
restrictedly/RB
to/TO
help/VB
those/DT
who/WP
want/JJ
to/TO
validate/VB
hits/VBZ
to/TO
determine/VB
the/DT
priority/NN
of/IN
subjects/NNS
of/IN
an/DT
assay/NN
./.
====================
Fig/NN
./.
====================
8/CD
shows/VBZ
the/DT
alignments/NNS
of/IN
the/DT
best/JJS
hits/VBZ
into/IN
each/DT
pharmacophore/NN
model/NN
;/:
all/DT
of/IN
the/DT
hits/NNS
map/VBP
well/RB
to/TO
the/DT
pharmacophore/NN
models/NNS
./.
====================
Of/IN
note/NN
,/,
the/DT
rank/NN
of/IN
the/DT
docking/NN
results/NNS
does/VBZ
not/RB
mean/JJ
pharmacophore/NN
fitness/RB
,/,
and/CC
all/DT
of/IN
the/DT
inhibitor/NN
compounds/NNS
we/PRP
found/VBD
here/RB
can/MD
be/VB
mapped/VBN
to/TO
the/DT
models/NNS
well/RB
./.
====================
The/DT
figure/NN
of/IN
pharmacophore/NN
alignment/NN
was/VBD
made/VBN
to/TO
provide/VB
an/DT
example/NN
showing/VBG
that/IN
our/PRP$
hits/NNS
can/MD
be/VB
mapped/VBN
properly/RB
./.
====================
In/IN
summary/NN
,/,
we/PRP
screened/VBD
more/RBR
than/IN
3/CD
million/NN
lead-like/JJ
compounds/NNS
by/IN
pharmacophore/NN
modeling/VBG
,/,
and/CC
1,338/NN
hits/VBZ
were/VBD
suggested/VBN
to/TO
be/VB
potential/JJ
inhibitors/NNS
of/IN
APE1/NN
./.
====================
However/RB
,/,
this/DT
work/NN
has/VBZ
a/DT
limitation/NN
,/,
due/JJ
to/TO
the/DT
lack/NN
of/IN
experimental/JJ
validation/NN
./.
====================
Nevertheless/RB
,/,
the/DT
list/NN
of/IN
hits/VBZ
in/IN
this/DT
work/NN
could/MD
reduce/VB
the/DT
time/NN
and/CC
cost/JJ
of/IN
researchers/NNS
who/WP
want/JJ
to/TO
develop/VB
novel/JJ
anticancer/JJ
drugs/NNS
inhibiting/VBG
the/DT
activity/NN
of/IN
APE1/NN
,/,
since/IN
we/PRP
prioritized/VBD
candidates/NNS
of/IN
the/DT
experiments/NNS
and/CC
since/IN
all/DT
of/IN
them/PRP
have/VBP
lead-like/IN
properties/NNS
,/,
which/WDT
means/NNS
that/IN
the/DT
hits/NNS
are/VBP
appropriate/JJ
for/IN
further/JJ
optimization/NN
and/CC
development/NN
into/IN
drugs/NNS
./.
====================
Currently/RB
,/,
there/EX
are/VBP
several/JJ
approaches/NNS
that/WDT
apply/RB
hits/VBZ
from/IN
a/DT
pharmacophore/NN
screen/NN
for/IN
further/JJ
development/NN
in/IN
to/TO
a/DT
novel/JJ
drug/NN
./.
====================
Fei/NNS
et/FW
al/JJ
./.
====================
[/(
26/CD
]/)
first/JJ
developed/VBD
a/DT
pharmacophore/NN
model/NN
of/IN
a/DT
drug/NN
target/NN
,/,
like/IN
our/PRP$
method/NN
;/:
then/RB
,/,
3D-quantitative/JJ
structure-activity/NN
relationship/NN
(/(
QSAR/NN
)/)
modeling/VBG
was/VBD
used/VBN
for/IN
validation/NN
and/CC
further/RB
virtual/JJ
screening/NN
./.
====================
Wieder/IN
et/FW
al/JJ
./.
====================
[/(
27/CD
]/)
proposed/VBN
a/DT
novel/JJ
approach/NN
combining/VBG
pharmacophore/NN
modeling/VBG
and/CC
molecular/JJ
dynamics/NNS
(/(
MD/NN
)/)
simulations/NNS
,/,
and/CC
they/PRP
showed/VBD
that/IN
their/PRP$
methods/NNS
were/VBD
likely/RB
to/TO
result/VB
in/IN
more/RBR
robust/JJ
hits/VBZ
./.
====================
Like/IN
these/DT
approaches/NNS
,/,
the/DT
results/NNS
from/IN
pharmacophore/NN
modeling/VBG
could/MD
be/VB
adopted/VBN
in/IN
other/JJ
in/IN
silico/NN
methods/NNS
,/,
such/JJ
as/IN
molecular/JJ
docking/NN
,/,
QSAR/NN
modeling/VBG
,/,
and/CC
MD/NN
simulation/JJ
./.
====================
It/PRP
is/VBZ
worth/NN
combining/VBG
these/DT
methods/NNS
and/CC
our/PRP$
results/NNS
to/TO
get/VB
more/RBR
robust/JJ
results/NNS
./.
====================
If/IN
further/RBR
integrative/JJ
approaches/NNS
and/CC
in/IN
vitro/FW
or/CC
vivo/FW
assays/NNS
of/IN
hits/NNS
validate/NN
our/PRP$
results/NNS
,/,
our/PRP$
method/NN
could/MD
be/VB
applied/VBN
to/TO
other/JJ
drug/NN
targets/NNS
,/,
in/IN
addition/NN
to/TO
APE1/NN
./.
====================
Outline/NN
of/IN
overall/JJ
procedures/NNS
of/IN
the/DT
screen/NN
to/TO
find/VB
potential/JJ
inhibitors/NNS
of/IN
apurinic/apyrimidinic/JJ
endonuclease/NN
1/CD
./.
====================
Clustering/NN
of/IN
molecules/NNS
for/IN
construction/NN
of/IN
pharmacophore/NN
models/NNS
./.
====================
Structures/NNS
of/IN
the/DT
49/CD
compounds/NNS
in/IN
group/NN
1/CD
used/VBN
to/TO
generate/VB
pharmacophore/NN
model/NN
1/CD
./.
====================
Structures/NNS
of/IN
the/DT
33/CD
compounds/NNS
in/IN
group/NN
2/CD
used/VBN
to/TO
generate/VB
pharmacophore/NN
model/NN
2/CD
./.
====================
Pharmacophore/NN
models/NNS
used/VBN
for/IN
screening/NN
./.
====================
Models/NNS
were/VBD
generated/VBN
by/IN
compounds/NNS
in/IN
group/NN
1/CD
(/(
A/NN
)/)
and/CC
group/NN
2/CD
(/(
B/NN
)/)
./.
====================
Distribution/NN
of/IN
predicted/VBN
binding/NN
affinities/NNS
by/IN
molecular/JJ
docking/NN
of/IN
potential/JJ
inhibitors/NNS
to/TO
apurinic/apyrimidinic/JJ
endonuclease/NN
1/CD
./.
====================
Structures/NNS
and/CC
scores/VBZ
of/IN
the/DT
screen/NN
of/IN
the/DT
top/NN
10/CD
hits/VBZ
./.
====================
Mapping/NN
of/IN
top/NN
10/CD
hits/VBZ
to/TO
pharmacophore/VB
models/NNS
./.
====================
(/(
A/NN
)/)
Model/NN
1/CD
./.
====================
(/(
B/NN
)/)
Model/NN
2/CD
./.
====================
